Space Telescope and Optical Reverberation Mapping Project. XI. Disk-wind Characteristics and Contributions to the Very Broad Emission Lines of NGC 5548

In 2014 the NGC 5548 Space Telescope and Optical Reverberation Mapping campaign discovered a two-month anomaly when variations in the absorption and emission lines decorrelated from continuum variations. During this time the soft X-ray part of the intrinsic spectrum had been strongly absorbed by a line-of-sight (LOS) obscurer, which was interpreted as the upper part of a disk wind. Our first paper showed that changes in the LOS obscurer produce the decorrelation between the absorption lines and the continuum. A second study showed that the base of the wind shields the BLR, leading to the emission-line decorrelation. In that study, we proposed the wind is normally transparent with no effect on the spectrum. Changes in the wind properties alter its shielding and affect the SED striking the BLR, producing the observed decorrelations. In this work, we investigate the impact of a translucent wind on the emission lines. We simulate the obscuration using XMM-Newton, NuSTAR, and HST observations to determine the physical characteristics of the wind. We find that a translucent wind can contribute a part of the He II and Fe K? emission. It has a modest optical depth to electron scattering, which explains the fainter far-side emission in the observed velocity delay maps. The wind produces the very broad base seen in the UV emission lines and may also be present in the Fe K? line. Our results highlight the importance of accounting for the effects of such winds in the analysis of the physics of the central engine

Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial

Background: Irbesartan, a long acting selective angiotensin-1 receptor inhibitor, in Marfan syndrome might reduce aortic dilatation, which is associated with dissection and rupture. We aimed to determine the effects of irbesartan on the rate of aortic dilatation in children and adults with Marfan syndrome. Methods: We did a placebo-controlled, double-blind randomised trial at 22 centres in the UK. Individuals aged 6–40 years with clinically confirmed Marfan syndrome were eligible for inclusion. Study participants were all given 75 mg open label irbesartan once daily, then randomly assigned to 150 mg of irbesartan (increased to 300 mg as tolerated) or matching placebo. Aortic diameter was measured by echocardiography at baseline and then annually. All images were analysed by a core laboratory blinded to treatment allocation. The primary endpoint was the rate of aortic root dilatation. This trial is registered with ISRCTN, number ISRCTN90011794. Findings: Between March 14, 2012, and May 1, 2015, 192 participants were recruited and randomly assigned to irbesartan (n=104) or placebo (n=88), and all were followed for up to 5 years. Median age at recruitment was 18 years (IQR 12–28), 99 (52%) were female, mean blood pressure was 110/65 mm Hg (SDs 16 and 12), and 108 (56%) were taking β blockers. Mean baseline aortic root diameter was 34·4 mm in the irbesartan group (SD 5·8) and placebo group (5·5). The mean rate of aortic root dilatation was 0·53 mm per year (95% CI 0·39 to 0·67) in the irbesartan group compared with 0·74 mm per year (0·60 to 0·89) in the placebo group, with a difference in means of −0·22 mm per year (−0·41 to −0·02, p=0·030). The rate of change in aortic Z score was also reduced by irbesartan (difference in means −0·10 per year, 95% CI −0·19 to −0·01, p=0·035). Irbesartan was well tolerated with no observed differences in rates of serious adverse events. Interpretation: Irbesartan is associated with a reduction in the rate of aortic dilatation in children and young adults with Marfan syndrome and could reduce the incidence of aortic complications